The Vytorin controversy exposes shortcomings of surrogate endpoints

The Vytorin controversy exposes shortcomings of surrogate endpoints.

Drugs are often approved, or used, based on their ability to change surrogate endpoints...blood pressure, lipids, serum glucose, etc.

These are often ASSUMED to reflect a drug's effectiveness.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote